Aveanna director Dr. Erica Schwartz resigns to become CDC Director

Aveanna Healthcare Holdings, Inc.

Dr. Erica Schwartz resigned from Aveanna's Board effective August 5, 2026, after nomination/confirmation as CDC Director.
Resignation not due to any disagreement with Company on operations, policies, or practices.
Schwartz was an independent Class III director and Chair of the Clinical Quality Committee.
No replacement named; board composition changes effective immediately.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Erica Schwartz

Director

AVAH · Aveanna Healthcare Holdings, Inc.

Effective: 2026-08-05
Filed: August 7, 2026, 4:43 PM ET

On August 5, 2026, Dr. Erica Schwartz, a Class III director of Aveanna Healthcare Holdings Inc. (the "Company"), notified the Company of her decision to resign from the Company's Board of Directors, effective immediately, in connection with her nomination and subsequent confirmation as the Director of the United States Centers of Disease Control and Prevention.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Erica Schwartz resigned as Director at Aveanna Healthcare Holdings, Inc..

Action: resigned
Role: Director

Exact text from the filing

On August 5, 2026, Dr. Erica Schwartz, a Class III director of Aveanna Healthcare Holdings Inc. (the "Company"), notified the Company of her decision to resign from the Company's Board of Directors, effective immediately, in connection with her nomination and subsequent confirmation as the Director of the United States Centers of Disease Control and Prevention.

View on SEC.gov

Aveanna Healthcare Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-340409

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.